Atrial FibrillationNCT03753139
Identification of Arrhythmias With One-time ECG
An observational study of Atrial Fibrillation and Heart Rate Fast, run by Kuopio University Hospital at 1 site in Finland.
Trial summary
In Western countries, every sixth person in their lifetime and 15,000 people in Finland have a new stroke each year. About every fourth stroke is based on cardiac embolism. Atrial fibrillation causes formation of thrombi in the left atrium with ensuing embolization in the cerebral and peripheral circulation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation, Heart Rate Fast, Heart Rate Low
- What is being tested?
- Heart rhythm monitoring with portable device
- Type of treatment
- Medical device
- How many people
- 260 participants
- Where
- 1 siteFinland
- Study dates
- 28 Nov 2018to 31 Jul 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: A total of 300 patients will be recruited in the research: 100 patients with normal sinus rhythm, 100 with atrial fibrillation, 50 with rapid rhythm (tachycardia, resting heart rate > 100 bpm) and 50 slow rhythms (bradycardia, resting heart rate< 50bpm).
Who may be able to join
- Patients treated for any reason in the emergency department of Kuopio University Hospital.
Who cannot join
- body mass index (BMI) over 35, implanted heart pacemaker device and a medical condition requiring immediate treatment that would be delayed by the study measurements.
Trial locations and contacts
1 site in 1 country.
About this study
In Western countries, every sixth person in their lifetime and 15,000 people in Finland have a new stroke each year. About every fourth stroke is based on cardiac embolism. Atrial fibrillation causes formation of thrombi in the left atrium with ensuing embolization in the cerebral and peripheral circulation.
This study investigates the suitability of measurement techniques and new calculation methods used in sport/wellness technology for the screening and diagnosis of atrial fibrillation and other arrhythmias. New measurement technologies, the one-time ECG measurement and pulse wristband measurement, are studied for their characteristics, data quality and rhythm recognition. Identifying latent arrhythmias with new self-monitoring technologies can significantly reduce the number of strokes (the latent arrhythmias causes about 25% of strokes).
Read more
The research will be accomplished in cooperation with the Kuopio University Hospital Emergency Department, the Heart Center, the Department of Applied Physics of the University of Eastern Finland and Heart2Save Ltd.
The results of the research project will be published in the scientific journals of medicine and medical technology and will be presented at scientific conferences of the respective fields. The research results of the project can be utilized by all companies in the medical technology industry, in particular companies that produce ECG measuring instruments and companies that produce rhythm recognition software.
Read the detailed description
The research aims to solve the following medical problems:
- Identifying and defining the type of atrial fibrillation is problematic due to its spontaneous occurrence and latency.
- Measurement devices for screening atrial fibrillation are poorly available.
The main research questions are:
- Can a single-lead ECG measurement be used to detect arrhythmias
- Find out the measurement locations (ECG leads) for single-lead ECG self-monitoring and evaluate the impact of measurement locations on usability and signal quality.
- Find out the measurement locations for single-lead ECG monitoring when the measurement is performed by another person (nurse or relative) and evaluate the impact of measurement locations on usability and signal quality.
- Find out the reliability of single-lead ECG measurement for the identification of atrial fibrillation.
- Find out the reliability of single-lead ECG measurement for identification of rapid (tachycardia) and slow heart rate (bradycardia).
- Can a wristband based on optical pulse registration be able to obtain reliable information about arrhythmias
- Find out the usability of the pulse wristband for the identification of atrial fibrillation.
- Find out the usability of the pulse wristband for the identification of rapid (tachycardia) and slow heart rate (bradycardia).
The purpose of the study's method development is to evaluate reliability of heart rate measurement in single-lead ECG and pulse wave measurement with healthy and patients with heart problems. The study develops computing methods based on lightweight measurement technology to reliably identify the most common cardiac arrhythmia, atrial fibrillation. The diagnosis and treatment of atrial fibrillation are decisive factors for preventing strokes.
Research patients have already undergone a 12-channel clinical ECG registration included in the normal treatment process. This 12-channel ECG is used for the identification of patients suitable for research and dividing to subgroups (normal rhythm, atrial fibrillation, rapid or slow rhythm).
In actual study measurements, a Holter-ECG device is attached on patient's chest using five wet electrodes to be used as golden standard for rhythm monitoring. The lightweight measurement methods are compared with the result of the Holter-ECG registration. In addition, photopletysmogram is placed on patient's wrist for PPG registration. Figure 1 shows illustrative examples of the study's measurements.
The researcher measures one minute recordings from two different measuring positions (flank and chest) with a one-time ECG measuring device. After that, the patient performs one minute self-monitoring measurements with one-time ECG device from the all three positions (thumbs, flank and chest) and also from the chest with jewel-ECG.
The study compares the ability of these lightweight measurement methods to detect different heart rhythms compared to the Holter registration.
The devices used for the measurement are:
- Faros 360 EKG sensor with wet electrodes (figure 1, device 1) (Mega Elektroniikka, http://www.megaemg.com/ Kuopio Suomi). Faros 360 Holter is CE and FDA 510(k) cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.
- Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Suomi). Movesense is CE cleared consumer device, which is used with two dy electrodes to the ECG measurement (Figure 1 devices 2 and 3). Movesense case; jewel and one-time ECG case.
- In the previous study (Afib24h), Valvira was reported and the research received permission for the clinical device study (Movesense + chest strap combination).
- For this study, Valira is reported for a clinical device study (Movesense + one-time ECG device combination)
- Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan Italia), which is CE cleared consumer device. Empatica E4 is also a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel (Figure 1 device 4).
- Samsung Gear S3 wearable (Samsung Electronics, Co., Ltd., www.samsung.com Soul Etelä-Korea) which is CE cleared consumer device. Gear S3 is also a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel.
The researcher attaches devices to the patient. After that, the researcher starts a 10-minute registration with Faros 360 (device 1) and Empatica E4 (device 4) devices. During a 10-minute measurement, the researcher measures one minute recordings from two different measuring positions with the Movesense ECG (device 2) 1. from the chest, sternum perpendicularly 2. from the chest, along the sternum. The patient then carries out one minute self-monitoring measurements 1. from the chest, sternum perpendicularly 2. from the chest, along the sternum 3. from the lower part of the flank 4. from thumbs and 5. from the chest with a jewel-ECG.
Heart rate detection by ECG measurement is most commonly done by the detection of QRS complexes. Numerous of these QRS detectors have been developed in recent decades. ECG measurement with dry electrodes involves considerably more movement disturbances, compared to the wet electrode measurements, as even the small movements of the device induce major changes to the ECG signal. In addition, especially when using thumbs as a measurement points, the EMG noise from the muscles is remarkably high compared to the wet electrode measurements.
This project utilizes the methods developed in the earlier mobile-ECG-project for noise and QRS detection to allow reliably detection of QRS complexes and heart rate irregularities in the dry electrode measurements.
In this study, the previously developed heart rate detection methods are validated by study's measurements of normal sinus rhythm, atrial fibrillation, and slow (bradycardia) and rapid (tachycardia) heart rate.
This study examines capability of pulse detection in detection of atrial fibrillation. The photopletysmogram measures the absorption of light in the tissue. The absorption of light into the blood is greater than the absorption into the surrounding tissue. When the heart beats, capillaries expand and contract based on blood volume changes. Photopletysmography allows the heart rate measurement by detecting changes in absorption.
Photopletysmgram, like a mobile-ECG device, is particularly sensitive to motion, even the small motion of led/photodiode induce major change in light intensity.
Also, physiological changes cause a disturbance in heart rate measurement, for example, as the vascular elasticity changes, the pulse time changes, resulting a disturbance in measurement.
Unlike the high-frequency pierced QRS complex, the pulse wave is a low-frequency up-down variation, which causes its own challenges for accurate heart rate measurement.
The atriums work insufficiently in atrial fibrillation therefore the ventricles are not completely filled with blood. In addition, atrial fibrillation causes the irregular conduction of impulses from atriums to the ventricles leading to pulse irregularity. The amount of blood pumped varies from one stroke to stroke, which makes the pulse wave detection challenging.
This project develops methods for accurate heart rate measurement from a pulse wave series.
The method development aims to take account of disturbances due to the motion of the meter, pulse wave irregularities typical of atrial fibrillation, and the challenges of slow (bradycardia) and rapid (tachycardia) heart rate detection.
The main goal of the method development is to determine the pulse so precisely that pulse irregularity due to atrial fibrillation can be distinguished from normal sinus rhythm and reliably detect rapid and slow heart rhythms.
In atrial fibrillation, electrical impulses conduct randomly to the ventricles, causing the heart rate to be irregular and uneven. A large campaign by the Heart Association "Feel your pulse - prevent the stroke" is based on heart rate or pulse recognition. Pulse recognition is of course the cheapest method to detect atrial fibrillation, but this method produces a large number of false positives. By ECG measurement, the detection of atrial fibrillation is much more reliable. Automated atrial fibrillation detection algorithms have been developed for this purpose.
Identification of the atrium activation in long-term Holter-ECG measurements is generally very challenging due to the poor signal-noise-ratio (motion, muscle-artefacts and partly overlapping much stronger ventricular activity). For this reason, most atrial fibrillation detection algorithms are based on the identification of pulse irregularity. For parametrization of the irregularity of the heart rate (RR-interval) has been introduced several relatively simple but reliable time-level methods. As an example, A RdR-based method wherein the RR intervals (heart rate) are represented as a function of consecutive RR interval changes (heart rate change) (Lian et al. 2011). The RdR-graph defines the fragmentation of the pattern resulting from irregular heart rate changes. In addition, there are methods that estimate RR time series internal coherence (Lee et al. 2011). Various nonlinear methods have also been introduced to parametrization of the heart rate variation, enabling the dynamics of the heart rate variation to be described more broadly (without limitation of the linearity assumption). One class of nonlinear methods are different entropy quantities, these are particularly interesting for the identification of atrial fibrillation and the irregular heart rate. Entropy quantities can be used to estimate the regularity and predictability of the RR time series. Typically, the reliable calculation of the entropy quantities requires a relatively long measurement time, but also entropy quantities that are suitable for the analysis of short measurements have been introduced (Lake \& Moorman 2011).
This research project develops new atrial fibrillation detection algorithms for the mobile-ECG measurement and pulse wave measurement on the basis of already existing methods. Algorithms must take into account atrial and ventricular premature complexes. Ignoring of these increases the irregularity of the RR time series and thus increases the number of false positive atrial fibrillation.
- Conditions
- Atrial Fibrillation, Heart Rate Fast, Heart Rate Low
- Being tested
- Heart rhythm monitoring with portable device
- Keywords
- Atrial fibrillation; detection; portable device; algorithms
- Medical subject headings
- Atrial Fibrillation, Tachycardia, Bradycardia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Heart rhythm monitoring with portable deviceDevice
The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.
- Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.
- Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.
- Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel.
- Samsung Gear S3 wearable (Samsung Electronics, Co., Soul, South Korea) which is CE cleared consumer device. Gear S3 is a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel.
| Study group | Role | What they receive |
|---|---|---|
| Atrial fibrillation | Patients with atrial fibrillation as recorded by Holter Receives: Device: Heart rhythm monitoring with portable device | |
| Sinus rhythm | Patients with sinus rhythm as recorded by Holter Receives: Device: Heart rhythm monitoring with portable device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Heart rhythm monitoring with single-lead ECG
Sensitivity and Specificity for the atrial fibrillation detection
Measured: 30 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Nov 2018
- Study start28 Nov 2018
- Primary completion28 Feb 2020
- Study completion31 Jul 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (24)Papers the sponsor has linked to this study.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 260 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kuopio University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University of Eastern Finland
- Responsible party
- Sponsor
- Investigators
- Tero J Martikainen, MD. PhD, Principal investigator, Kuopio University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03753139
- Sponsor's protocol ID
- KUH507P002
- Status last verified
- Apr 2021
- First submitted
- 22 Nov 2018
- Last updated
- 30 Apr 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Amann A, Tratnig R, Unterkofler K. Reliability of old and new ventricular fibrillation detection algorithms for automated external defibrillators. Biomed Eng Online. 2005 Oct 27;4:60. doi: 10.1186/1475-925X-4-60.
PubMed 16253134Barro S, Ruiz R, Cabello D, Mira J. Algorithmic sequential decision-making in the frequency domain for life threatening ventricular arrhythmias and imitative artefacts: a diagnostic system. J Biomed Eng. 1989 Jul;11(4):320-8. doi: 10.1016/0141-5425(89)90067-8.
PubMed 2755113Cabello D, Barro S, Salceda JM, Ruiz R, Mira J. Fuzzy K-nearest neighbor classifiers for ventricular arrhythmia detection. Int J Biomed Comput. 1991 Feb;27(2):77-93. doi: 10.1016/0020-7101(91)90089-w.
PubMed 2032755Chen SW. A two-stage discrimination of cardiac arrhythmias using a total least squares-based prony modeling algorithm. IEEE Trans Biomed Eng. 2000 Oct;47(10):1317-27. doi: 10.1109/10.871404.
PubMed 11059166al-Fahoum AS, Howitt I. Combined wavelet transformation and radial basis neural networks for classifying life-threatening cardiac arrhythmias. Med Biol Eng Comput. 1999 Sep;37(5):566-73. doi: 10.1007/BF02513350.
PubMed 10723893Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S; Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006 Aug;27(16):1979-2030. doi: 10.1093/eurheartj/ehl176. No abstract available.
PubMed 16885201Ge D, Srinivasan N, Krishnan SM. Cardiac arrhythmia classification using autoregressive modeling. Biomed Eng Online. 2002 Nov 13;1:5. doi: 10.1186/1475-925x-1-5.
PubMed 12473180Jekova I. Comparison of five algorithms for the detection of ventricular fibrillation from the surface ECG. Physiol Meas. 2000 Nov;21(4):429-39. doi: 10.1088/0967-3334/21/4/301.
PubMed 11110242Lake DE, Moorman JR. Accurate estimation of entropy in very short physiological time series: the problem of atrial fibrillation detection in implanted ventricular devices. Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H319-25. doi: 10.1152/ajpheart.00561.2010. Epub 2010 Oct 29.
PubMed 21037227Lee J, Nam Y, McManus DD, Chon KH. Time-varying coherence function for atrial fibrillation detection. IEEE Trans Biomed Eng. 2013 Oct;60(10):2783-93. doi: 10.1109/TBME.2013.2264721. Epub 2013 May 22.
PubMed 23708769Li C, Zheng C, Tai C. Detection of ECG characteristic points using wavelet transforms. IEEE Trans Biomed Eng. 1995 Jan;42(1):21-8. doi: 10.1109/10.362922.
PubMed 7851927Lian J, Wang L, Muessig D. A simple method to detect atrial fibrillation using RR intervals. Am J Cardiol. 2011 May 15;107(10):1494-7. doi: 10.1016/j.amjcard.2011.01.028. Epub 2011 Mar 17.
PubMed 21420064Lipponen JA, Tarvainen MP, Laitinen T, Lyyra-Laitinen T, Karjalainen PA. A principal component regression approach for estimation of ventricular repolarization characteristics. IEEE Trans Biomed Eng. 2010 May;57(5):1062-9. doi: 10.1109/TBME.2009.2037492. Epub 2010 Feb 5.
PubMed 20142157Lipponen JA, Kemppainen J, Karjalainen PA, Laitinen T, Mikola H, Karki T, Tarvainen MP. Dynamic estimation of cardiac repolarization characteristics during hypoglycemia in healthy and diabetic subjects. Physiol Meas. 2011 Jun;32(6):649-60. doi: 10.1088/0967-3334/32/6/003. Epub 2011 Apr 20.
PubMed 21508439Lipponen JA, Tarvainen MP. Principal component model for maternal ECG extraction in fetal QRS detection. Physiol Meas. 2014 Aug;35(8):1637-48. doi: 10.1088/0967-3334/35/8/1637. Epub 2014 Jul 29.
PubMed 25069651
Study at a glance
From the registry record, last updated by the sponsor on 30 Apr 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identification of Arrhythmias With One-time ECG
- ClinicalTrials.gov ID
- NCT03753139
- Acronym / sponsor ID
- KUH507P002
- Conditions
- Atrial Fibrillation, Heart Rate Fast, Heart Rate Low
- Keywords
- Atrial fibrillation; detection; portable device; algorithms
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 260 participants (actual)
- Lead sponsor
- Kuopio University HospitalUniversity, hospital or other
- Collaborators
- University of Eastern Finland
- Study start
- 28 Nov 2018 (actual)
- Primary completion
- 28 Feb 2020 (actual)
- Study completion
- 31 Jul 2020 (actual)
- First posted
- 26 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In Western countries, every sixth person in their lifetime and 15,000 people in Finland have a new stroke each year. About every fourth stroke is based on cardiac embolism. Atrial fibrillation causes formation of thrombi in the left atrium with ensuing embolization in the cerebral and peripheral circulation.
This study investigates the suitability of measurement techniques and new calculation methods used in sport/wellness technology for the screening and diagnosis of atrial fibrillation and other arrhythmias. New measurement technologies, the one-time ECG measurement and pulse wristband measurement, are studied for their characteristics, data quality and rhythm recognition. Identifying latent arrhythmias with new self-monitoring technologies can significantly reduce the number of strokes (the latent arrhythmias causes about 25% of strokes).
The research will be accomplished in cooperation with the Kuopio University Hospital Emergency Department, the Heart Center, the Department of Applied Physics of the University of Eastern Finland and Heart2Save Ltd.
The results of the research project will be published in the scientific journals of medicine and medical technology and will be presented at scientific conferences of the respective fields. The research results of the project can be utilized by all companies in the medical technology industry, in particular companies that produce ECG measuring instruments and companies that produce rhythm recognition software.
Detailed description
The research aims to solve the following medical problems:
- Identifying and defining the type of atrial fibrillation is problematic due to its spontaneous occurrence and latency.
- Measurement devices for screening atrial fibrillation are poorly available.
The main research questions are:
- Can a single-lead ECG measurement be used to detect arrhythmias
- Find out the measurement locations (ECG leads) for single-lead ECG self-monitoring and evaluate the impact of measurement locations on usability and signal quality.
- Find out the measurement locations for single-lead ECG monitoring when the measurement is performed by another person (nurse or relative) and evaluate the impact of measurement locations on usability and signal quality.
- Find out the reliability of single-lead ECG measurement for the identification of atrial fibrillation.
- Find out the reliability of single-lead ECG measurement for identification of rapid (tachycardia) and slow heart rate (bradycardia).
- Can a wristband based on optical pulse registration be able to obtain reliable information about arrhythmias
- Find out the usability of the pulse wristband for the identification of atrial fibrillation.
- Find out the usability of the pulse wristband for the identification of rapid (tachycardia) and slow heart rate (bradycardia).
The purpose of the study's method development is to evaluate reliability of heart rate measurement in single-lead ECG and pulse wave measurement with healthy and patients with heart problems. The study develops computing methods based on lightweight measurement technology to reliably identify the most common cardiac arrhythmia, atrial fibrillation. The diagnosis and treatment of atrial fibrillation are decisive factors for preventing strokes.
Research patients have already undergone a 12-channel clinical ECG registration included in the normal treatment process. This 12-channel ECG is used for the identification of patients suitable for research and dividing to subgroups (normal rhythm, atrial fibrillation, rapid or slow rhythm).
In actual study measurements, a Holter-ECG device is attached on patient's chest using five wet electrodes to be used as golden standard for rhythm monitoring. The lightweight measurement methods are compared with the result of the Holter-ECG registration. In addition, photopletysmogram is placed on patient's wrist for PPG registration. Figure 1 shows illustrative examples of the study's measurements.
The researcher measures one minute recordings from two different measuring positions (flank and chest) with a one-time ECG measuring device. After that, the patient performs one minute self-monitoring measurements with one-time ECG device from the all three positions (thumbs, flank and chest) and also from the chest with jewel-ECG.
The study compares the ability of these lightweight measurement methods to detect different heart rhythms compared to the Holter registration.
The devices used for the measurement are:
- Faros 360 EKG sensor with wet electrodes (figure 1, device 1) (Mega Elektroniikka, http://www.megaemg.com/ Kuopio Suomi). Faros 360 Holter is CE and FDA 510(k) cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.
- Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Suomi). Movesense is CE cleared consumer device, which is used with two dy electrodes to the ECG measurement (Figure 1 devices 2 and 3). Movesense case; jewel and one-time ECG case.
- In the previous study (Afib24h), Valvira was reported and the research received permission for the clinical device study (Movesense + chest strap combination).
- For this study, Valira is reported for a clinical device study (Movesense + one-time ECG device combination)
- Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan Italia), which is CE cleared consumer device. Empatica E4 is also a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel (Figure 1 device 4).
- Samsung Gear S3 wearable (Samsung Electronics, Co., Ltd., www.samsung.com Soul Etelä-Korea) which is CE cleared consumer device. Gear S3 is also a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel.
The researcher attaches devices to the patient. After that, the researcher starts a 10-minute registration with Faros 360 (device 1) and Empatica E4 (device 4) devices. During a 10-minute measurement, the researcher measures one minute recordings from two different measuring positions with the Movesense ECG (device 2) 1. from the chest, sternum perpendicularly 2. from the chest, along the sternum. The patient then carries out one minute self-monitoring measurements 1. from the chest, sternum perpendicularly 2. from the chest, along the sternum 3. from the lower part of the flank 4. from thumbs and 5. from the chest with a jewel-ECG.
Heart rate detection by ECG measurement is most commonly done by the detection of QRS complexes. Numerous of these QRS detectors have been developed in recent decades. ECG measurement with dry electrodes involves considerably more movement disturbances, compared to the wet electrode measurements, as even the small movements of the device induce major changes to the ECG signal. In addition, especially when using thumbs as a measurement points, the EMG noise from the muscles is remarkably high compared to the wet electrode measurements.
This project utilizes the methods developed in the earlier mobile-ECG-project for noise and QRS detection to allow reliably detection of QRS complexes and heart rate irregularities in the dry electrode measurements.
In this study, the previously developed heart rate detection methods are validated by study's measurements of normal sinus rhythm, atrial fibrillation, and slow (bradycardia) and rapid (tachycardia) heart rate.
This study examines capability of pulse detection in detection of atrial fibrillation. The photopletysmogram measures the absorption of light in the tissue. The absorption of light into the blood is greater than the absorption into the surrounding tissue. When the heart beats, capillaries expand and contract based on blood volume changes. Photopletysmography allows the heart rate measurement by detecting changes in absorption.
Photopletysmgram, like a mobile-ECG device, is particularly sensitive to motion, even the small motion of led/photodiode induce major change in light intensity.
Also, physiological changes cause a disturbance in heart rate measurement, for example, as the vascular elasticity changes, the pulse time changes, resulting a disturbance in measurement.
Unlike the high-frequency pierced QRS complex, the pulse wave is a low-frequency up-down variation, which causes its own challenges for accurate heart rate measurement.
The atriums work insufficiently in atrial fibrillation therefore the ventricles are not completely filled with blood. In addition, atrial fibrillation causes the irregular conduction of impulses from atriums to the ventricles leading to pulse irregularity. The amount of blood pumped varies from one stroke to stroke, which makes the pulse wave detection challenging.
This project develops methods for accurate heart rate measurement from a pulse wave series.
The method development aims to take account of disturbances due to the motion of the meter, pulse wave irregularities typical of atrial fibrillation, and the challenges of slow (bradycardia) and rapid (tachycardia) heart rate detection.
The main goal of the method development is to determine the pulse so precisely that pulse irregularity due to atrial fibrillation can be distinguished from normal sinus rhythm and reliably detect rapid and slow heart rhythms.
In atrial fibrillation, electrical impulses conduct randomly to the ventricles, causing the heart rate to be irregular and uneven. A large campaign by the Heart Association "Feel your pulse - prevent the stroke" is based on heart rate or pulse recognition. Pulse recognition is of course the cheapest method to detect atrial fibrillation, but this method produces a large number of false positives. By ECG measurement, the detection of atrial fibrillation is much more reliable. Automated atrial fibrillation detection algorithms have been developed for this purpose.
Identification of the atrium activation in long-term Holter-ECG measurements is generally very challenging due to the poor signal-noise-ratio (motion, muscle-artefacts and partly overlapping much stronger ventricular activity). For this reason, most atrial fibrillation detection algorithms are based on the identification of pulse irregularity. For parametrization of the irregularity of the heart rate (RR-interval) has been introduced several relatively simple but reliable time-level methods. As an example, A RdR-based method wherein the RR intervals (heart rate) are represented as a function of consecutive RR interval changes (heart rate change) (Lian et al. 2011). The RdR-graph defines the fragmentation of the pattern resulting from irregular heart rate changes. In addition, there are methods that estimate RR time series internal coherence (Lee et al. 2011). Various nonlinear methods have also been introduced to parametrization of the heart rate variation, enabling the dynamics of the heart rate variation to be described more broadly (without limitation of the linearity assumption). One class of nonlinear methods are different entropy quantities, these are particularly interesting for the identification of atrial fibrillation and the irregular heart rate. Entropy quantities can be used to estimate the regularity and predictability of the RR time series. Typically, the reliable calculation of the entropy quantities requires a relatively long measurement time, but also entropy quantities that are suitable for the analysis of short measurements have been introduced (Lake \& Moorman 2011).
This research project develops new atrial fibrillation detection algorithms for the mobile-ECG measurement and pulse wave measurement on the basis of already existing methods. Algorithms must take into account atrial and ventricular premature complexes. Ignoring of these increases the irregularity of the RR time series and thus increases the number of false positive atrial fibrillation.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Atrial fibrillation | – | Device: Heart rhythm monitoring with portable devicePatients with atrial fibrillation as recorded by Holter |
| Sinus rhythm | – | Device: Heart rhythm monitoring with portable devicePatients with sinus rhythm as recorded by Holter |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- A total of 300 patients will be recruited in the research: 100 patients with normal sinus rhythm, 100 with atrial fibrillation, 50 with rapid rhythm (tachycardia, resting heart rate > 100 bpm) and 50 slow rhythms (bradycardia, resting heart rate< 50bpm).
Key inclusion criteria (1 listed)
- Patients treated for any reason in the emergency department of Kuopio University Hospital.
Key exclusion criteria (1 listed)
- body mass index (BMI) over 35, implanted heart pacemaker device and a medical condition requiring immediate treatment that would be delayed by the study measurements.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Heart rhythm monitoring with portable deviceThe study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration. 1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes. 2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement. 3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel. 4. Samsung Gear S3 wearable (Samsung Electronics, Co., Soul, South Korea) which is CE cleared consumer device. Gear S3 is a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel. | Device | Atrial fibrillation, Sinus rhythm |
Primary outcome
Heart rhythm monitoring with single-lead ECG
Time frame: 30 minutes
Sensitivity and Specificity for the atrial fibrillation detection
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Apr 2021.
- Background: PubMed 16253134Amann A, Tratnig R, Unterkofler K. Reliability of old and new ventricular fibrillation detection algorithms for automated external defibrillators. Biomed Eng Online. 2005 Oct 27;4:60. doi: 10.1186/1475-925X-4-60.
- Background: PubMed 2755113Barro S, Ruiz R, Cabello D, Mira J. Algorithmic sequential decision-making in the frequency domain for life threatening ventricular arrhythmias and imitative artefacts: a diagnostic system. J Biomed Eng. 1989 Jul;11(4):320-8. doi: 10.1016/0141-5425(89)90067-8.
- Background: PubMed 2032755Cabello D, Barro S, Salceda JM, Ruiz R, Mira J. Fuzzy K-nearest neighbor classifiers for ventricular arrhythmia detection. Int J Biomed Comput. 1991 Feb;27(2):77-93. doi: 10.1016/0020-7101(91)90089-w.
- Background: PubMed 11059166Chen SW. A two-stage discrimination of cardiac arrhythmias using a total least squares-based prony modeling algorithm. IEEE Trans Biomed Eng. 2000 Oct;47(10):1317-27. doi: 10.1109/10.871404.
- Background: PubMed 10723893al-Fahoum AS, Howitt I. Combined wavelet transformation and radial basis neural networks for classifying life-threatening cardiac arrhythmias. Med Biol Eng Comput. 1999 Sep;37(5):566-73. doi: 10.1007/BF02513350.
- Background: PubMed 16885201Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S; Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006 Aug;27(16):1979-2030. doi: 10.1093/eurheartj/ehl176. No abstract available.
- Background: PubMed 12473180Ge D, Srinivasan N, Krishnan SM. Cardiac arrhythmia classification using autoregressive modeling. Biomed Eng Online. 2002 Nov 13;1:5. doi: 10.1186/1475-925x-1-5.
- Background: PubMed 11110242Jekova I. Comparison of five algorithms for the detection of ventricular fibrillation from the surface ECG. Physiol Meas. 2000 Nov;21(4):429-39. doi: 10.1088/0967-3334/21/4/301.
- Background: PubMed 21037227Lake DE, Moorman JR. Accurate estimation of entropy in very short physiological time series: the problem of atrial fibrillation detection in implanted ventricular devices. Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H319-25. doi: 10.1152/ajpheart.00561.2010. Epub 2010 Oct 29.
- Background: PubMed 23708769Lee J, Nam Y, McManus DD, Chon KH. Time-varying coherence function for atrial fibrillation detection. IEEE Trans Biomed Eng. 2013 Oct;60(10):2783-93. doi: 10.1109/TBME.2013.2264721. Epub 2013 May 22.
- Background: PubMed 7851927Li C, Zheng C, Tai C. Detection of ECG characteristic points using wavelet transforms. IEEE Trans Biomed Eng. 1995 Jan;42(1):21-8. doi: 10.1109/10.362922.
- Background: PubMed 21420064Lian J, Wang L, Muessig D. A simple method to detect atrial fibrillation using RR intervals. Am J Cardiol. 2011 May 15;107(10):1494-7. doi: 10.1016/j.amjcard.2011.01.028. Epub 2011 Mar 17.
- Individual participant dataSharing planned: No
Related trials for Atrial Fibrillation
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruitingObservational study
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
Concomitant Procedures, Atrial Fibrillation
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Ischemic Stroke, Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tero J Martikainen, MD. PhD principal investigator
Kuopio University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atrial Fibrillation and Heart Rate Fast, run by Kuopio University Hospital at 1 site in Finland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Heart rhythm monitoring with single-lead ECG (time frame: 30 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03753139, which also lists 24 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2021.